Swissmedic lässt IFINWIL® für Kinder mit Hochrisiko-Neuroblastom zu

Norgine Austria Belgium France Germany Italy Netherlands Spain Switzerland United Kingdom England Australia

IFINWIL ® : jetzt auch in der Schweiz zugelassen1Neun von zehn Fällen von Neuroblastom treten bei Kindern unter fünf Jahren auf2Die durchschnittliche Überlebensrate von Kindern mit HRNB beträgt nur 50 %2Abgerufen im Juli 2025 
2. https://www.solvingkidscancer.org.uk/neuroblastoma/neuroblastoma-statistics/. Abgerufen im Juni 2025. 
3. Neuroblastoma Treatment (PDQ®) - NCI
4. Steven G. DuBois et al. High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes. Am Soc Clin Oncol Educ Book  42, 768-780(2022). 
5. https://rarediseases.info.nih.gov/diseases/7185/neuroblastoma. Abgerufen im Juni 2025 
6. Herd F, Basta NO, McNally RJQ, Tweddle DA. A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma. Eur J Cancer. April 2019;111:50-58. 
7. https://www.ncbi.nlm.nih.gov/books/NBK448111/ Zugriff im Juni 2025
8. Clinical Trial NCT02395666; Preventative trial of difluoromethylornithine (DFMO) in high risk patients with neuroblastoma that is in remission. Erhältlich bei: Study Details | Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission | ClinicalTrials.gov.
9. Meyskens FL Jr, Gerner EW. Development of Difluoromethylornithine (DFMO) as a Chemoprevention Agent. Clin Cancer Res. 5. Mai 1999 (5):945-51 
10. Basta NO, Halliday GC, Makin G, Birch J, Feltbower R, Bown N, et al. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. Br J Cancer. 2016;115:1048-57. 
11. Desai A, et al. Outcomes Following GD2-Directed Post consolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. J Clin Oncol. Juli 2022; JCO2102478. 
12. Basta NO, Halliday GC, Makin G, et al. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. Br J Cancer. 2016;115(9):1048-1057. doi:10.1038/bjc.2016.302. 
13. London WB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, et al. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials. Cancer. 2017;123:4914-23. 
14. FDA approves eflornithine for adult and pediatric patients with high-risk neuroblastoma | FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-eflornithine-adult-and-pediatric-patients-high-risk-neuroblastoma?s=09, ccessed 04.07.25

Logo - https://mma.prnewswire.com/media/597589/4648918/Norgine_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/swissmedic-lasst-ifinwil-eflornithin-fur-kinder-mit-hochrisiko-neuroblastom-hrnb-zu-302499396.html